Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.

Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S.

Eur J Cancer. 2012 Dec;48(18):3405-13. doi: 10.1016/j.ejca.2012.06.021. Epub 2012 Jul 26.

2.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
3.

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.

Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Sep 1;18(17):4753-63. doi: 10.1158/1078-0432.CCR-11-3210. Epub 2012 Jul 2.

4.

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.

Mol Cancer. 2014 May 31;13:135. doi: 10.1186/1476-4598-13-135.

5.

TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.

Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S.

PLoS One. 2011;6(9):e25062. doi: 10.1371/journal.pone.0025062. Epub 2011 Sep 20.

6.

Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Apr 15;18(8):2257-68. doi: 10.1158/1078-0432.CCR-11-2410. Epub 2012 Feb 22.

7.

Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.

Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu K, Meyerhardt JA, Fuchs CS, Harris CC, Qian ZR, Ogino S.

Ann Surg Oncol. 2015 Apr;22(4):1226-35. doi: 10.1245/s10434-014-4159-7. Epub 2014 Oct 18.

8.

Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.

Kakar S, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS.

Mod Pathol. 2012 Jul;25(7):1040-7. doi: 10.1038/modpathol.2012.44. Epub 2012 Apr 20.

9.

Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer.

Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S.

Ann Surg Oncol. 2012 Jun;19(6):1944-53. doi: 10.1245/s10434-011-2174-5. Epub 2011 Dec 22.

10.

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ.

Gastroenterology. 2013 Aug;145(2):348-56.e1-2. doi: 10.1053/j.gastro.2013.05.001. Epub 2013 May 7.

11.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.

Gut. 2009 Jan;58(1):90-6. doi: 10.1136/gut.2008.155473. Epub 2008 Oct 2.

12.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2765-72. doi: 10.1158/1055-9965.EPI-09-0490. Epub 2009 Sep 29.

13.

Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S.

Int J Cancer. 2012 Sep 1;131(5):1169-78. doi: 10.1002/ijc.26495. Epub 2011 Nov 19.

14.

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2009 Sep 20;27(27):4591-8. doi: 10.1200/JCO.2009.22.8858. Epub 2009 Aug 24.

15.

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.

Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S.

Gut. 2012 Jun;61(6):847-54. doi: 10.1136/gutjnl-2011-300865. Epub 2012 Mar 17.

16.

CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.

Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S.

Int J Cancer. 2010 Jun 15;126(12):2863-73. doi: 10.1002/ijc.24908.

17.

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.

Bae JM, Kim JH, Cho NY, Kim TY, Kang GH.

Br J Cancer. 2013 Aug 20;109(4):1004-12. doi: 10.1038/bjc.2013.430. Epub 2013 Jul 30.

18.

Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.

Gawlick U, Lu KC, Douthit MA, Diggs BS, Schuff KG, Herzig DO, Tsikitis VL.

Am J Surg. 2013 May;205(5):608-12; discussion 612. doi: 10.1016/j.amjsurg.2013.01.029.

PMID:
23592171
19.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

20.

Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.

Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.

J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.

PMID:
21660972
Items per page

Supplemental Content

Write to the Help Desk